Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 6/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | SOD1 | P00441 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359232 | 1.00 | HTR1A (0.70) | HTR1AKMT2AMEN1DRD4DRD2 | |
| SCHEMBL6350240 | 0.88 | DRD4 (0.77) | HTR1ADRD4DRD2GFER | |
| SCHEMBL6350236 | 0.88 | DRD4 (0.77) | HTR1ADRD4DRD2GFER | |
| SCHEMBL6359138 | 0.87 | DRD4 (0.71) | HTR1ADRD4DRD2HTR2A | |
| SCHEMBL6359142 | 0.87 | DRD4 (0.71) | HTR1ADRD4DRD2HTR2A | |
| SCHEMBL6353885 | 0.86 | DRD4 (0.83) | HTR1AKMT2AMEN1DRD4DRD2 | |
| SCHEMBL6353883 | 0.86 | DRD4 (0.83) | HTR1AKMT2AMEN1DRD4DRD2 | |
| SCHEMBL6358223 | 0.82 | HTR1A (1.00) | HTR1AKMT2AMEN1DRD2HTR2A | |
| SCHEMBL6351477 | 0.81 | DRD4 (0.76) | HTR1AKMT2ADRD4DRD2HTR2A | |
| SCHEMBL6351475 | 0.81 | DRD4 (0.76) | HTR1AKMT2ADRD4DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | HTR1A 871/4885KMT2A 1762/4885MEN1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.